Top

Open Access 24-03-2024 | Psoriatic Arthritis | Review

Endothelial dysfunction and risk factors for atherosclerosis in psoriatic arthritis: overview and comparison with rheumatoid arthritis

Authors: Konrad Kaleta, Julia Krupa, Wiktoria Suchy, Anna Sopel, Mariusz Korkosz, Jarosław Nowakowski

Published in: Rheumatology International

Abstract

Endothelial dysfunction (ED) is defined as an impairment in the vasodilatory, anti-thrombotic, and anti-inflammatory properties of the cells that make up the lining of blood vessels. ED is considered a key step in the development of atherosclerotic cardiovascular disease. The association between ED and systemic inflammatory diseases is well established. However, the prevalence and clinical significance of ED in psoriatic arthritis (PsA) have been investigated to a lesser extent. This review aims to explore the link between ED and PsA, including ED in macro- and microcirculation, as well as risk factors for its occurrence in PsA and its relationship with atherosclerosis in PsA. Furthermore, the ED in PsA was compared with that of rheumatoid arthritis (RA). Regarding ED in the microcirculation, the coronary flow reserve was found to be significantly reduced in individuals with PsA. The relationship between PsA and macrovascular ED is more pronounced, along with more advanced atherosclerosis detected in patients with PsA. These results are consistent with those obtained in RA studies. On the other hand, arterial stiffness and signs of vascular remodeling were found more frequently in RA than in PsA, with the potential role of efficient anti-TNF treatment in patients with PsA and psoriasis explaining this finding. The impact of ED on cardiovascular diseases and the burden of this risk caused independently by PsA have not yet been precisely established, however, this group of patients requires special attention with regard to cardiovascular events.

Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriatic arthritis. N Engl J Med 376:957–970. https://doi.org/10.1056/NEJMra1505557CrossRefPubMed

Mease PJ, Armstrong AW (2014) Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs 74:423–441. https://doi.org/10.1007/s40265-014-0191-yCrossRefPubMedPubMedCentral

Coates LC, Helliwell PS (2017) Psoriatic arthritis: state of the art review. Clin Med 17:65–70. https://doi.org/10.7861/clinmedicine.17-1-65CrossRef

Ciocon DH, Kimball AB (2007) Psoriasis and psoriatic arthritis: separate or one and the same? Br J Dermatol 157:850–860. https://doi.org/10.1111/j.1365-2133.2007.08148.xCrossRefPubMed

Atzeni F, Turiel M, Boccassini L et al (2011) Cardiovascular involvement in psoriatic arthritis. Reumatismo 63:148–154. https://doi.org/10.4081/reumatismo.2011.148CrossRefPubMed

Deanfield J, Donald A, Ferri C et al (2005) Endothelial function and dysfunction. Part I: methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens 23:7–17. https://doi.org/10.1097/00004872-200501000-00004CrossRefPubMed

di Minno MND, Ambrosino P, Lupoli R et al (2015) Cardiovascular risk markers in patients with psoriatic arthritis: a meta-analysis of literature studies. Ann Med 47:346–353. https://doi.org/10.3109/07853890.2015.1031822CrossRefPubMed

Han C, Robinson DW, Hackett MV et al (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33:2167–2172PubMed

Jamil M, Aslam R, Patel A et al (2021) Prevalence and extent of subclinical atherosclerosis and associated cardiovascular risk factors in adult patients with psoriatic arthritis: a systematic review. Cureus. https://doi.org/10.7759/cureus.16853CrossRefPubMedPubMedCentral

10.

Gasparyan AY, Ayvazyan L, Blackmore H et al (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409–1417. https://doi.org/10.1007/s00296-011-1999-3CrossRefPubMed

11.

Atzeni F, Sarzi-Puttini P, Sitia S et al (2011) Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis. J Rheumatol 38:1661–1664. https://doi.org/10.3899/jrheum.100893CrossRefPubMed

12.

Mahfouz RA, Mostafa T, Fahmy DS (2014) Impact of the neutrophil-to-lymphocyte ratio on coronary flow reserve and incipient myocardial dysfunction in patients with psoriatic arthritis. J Arthritis 03:1–5. https://doi.org/10.4172/2167-7921.1000119CrossRef

13.

Piaserico S, Osto E, Famoso G et al (2019) Long-term prognostic value of coronary flow reserve in psoriasis patients. Atherosclerosis 289:57–63. https://doi.org/10.1016/j.atherosclerosis.2019.08.009CrossRefPubMed

14.

Ikonomidis I, Pavlidis G, Katogiannis K et al (2022) Differences in coronary flow reserve and flow-mediated dilation between plaque psoriasis and psoriatic arthritis. Eur Heart J 43:2643. https://doi.org/10.1093/eurheartj/ehac544.2643CrossRef

15.

Murdaca G, Bezante G, Penza E et al (2016) Endothelial dysfunction in psoriatic arthritis: evaluation by endothelial-dependent flow-mediated dilation and coronary flow reserve. Ann Rheum Dis 75:600. https://doi.org/10.1136/annrheumdis-2016-eular.5725CrossRef

16.

Piaserico S, Papadavid E, Cecere A et al (2023) Coronary microvascular dysfunction in asymptomatic patients with severe psoriasis. J Invest Dermatol 143:1929-1936.e2. https://doi.org/10.1016/j.jid.2023.02.037CrossRefPubMed

17.

Piaserico S, Osto E, Famoso G et al (2016) Treatment with tumor necrosis factor inhibitors restores coronary microvascular function in young patients with severe psoriasis. Atherosclerosis 251:25–30. https://doi.org/10.1016/j.atherosclerosis.2016.05.036CrossRefPubMed

18.

Moroni L, Selmi C, Angelini C et al (2017) Evaluation of endothelial function by flow-mediated dilation: a comprehensive review in rheumatic disease. Arch Immunol Ther Exp (Warsz) 65:463–475. https://doi.org/10.1007/s00005-017-0465-7CrossRefPubMed

19.

Yilmazer B, Sahin T, Unlu BÖ et al (2015) Investigation of subclinical atherosclerosis in psoriatic arthritis patients with minimal disease activity. Rheumatol Int 35:1385–1392. https://doi.org/10.1007/s00296-015-3228-yCrossRefPubMed

20.

Gonzalez-Juanatey C, Llorca J, Miranda-Filloy JA et al (2007) Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Care Res (Hoboken) 57:287–293. https://doi.org/10.1002/art.22530CrossRef

21.

Bilgen ŞA, Kalyoncu U, Erden A et al (2018) Assessment of subclinical atherosclerosis in psoriatic arthritis patients without clinically overt cardiovascular disease or traditional atherosclerosis risk factors. Turk Kardiyol Dern Ars 46:358–365. https://doi.org/10.5543/tkda.2018.36169CrossRef

22.

Turoňová L, Kubejová K, Vorčáková K et al (2018) Endothelial dysfunction in children with juvenile psoriatic arthritis. Acta Medica (Hradec Kralove) 61:79–85. https://doi.org/10.14712/18059694.2018.122CrossRefPubMed

23.

Sharma A, Reddy MH, Sharma K et al (2014) Study of endothelial dysfunction in patients of psoriatic arthritis by flow mediated and nitroglycerine mediated dilatation of brachial artery. Int J Rheum Dis 19:300–304. https://doi.org/10.1111/1756-185X.12336CrossRefPubMed

24.

Verma S, Wang CH, Li SH et al (2002) A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106:913–919. https://doi.org/10.1161/01.CIR.0000029802.88087.5ECrossRefPubMed

25.

Dimitroulas T, Sandoo A, Kitas GD (2012) Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases. Int J Mol Sci 13:12315–12335. https://doi.org/10.3390/ijms131012315CrossRefPubMedPubMedCentral

26.

Shang Q, Tam LS, Sanderson JE et al (2012) Increase in ventricular-arterial stiffness in patients with psoriatic arthritis. Rheumatology (Oxford) 51:2215–2223. https://doi.org/10.1093/rheumatology/kes213CrossRefPubMed

27.

Patschan D, Sugiarto N, Henze E et al (2018) Early endothelial progenitor cells and vascular stiffness in psoriasis and psoriatic arthritis. Eur J Med Res 23:56. https://doi.org/10.1186/s40001-018-0352-7CrossRefPubMedPubMedCentral

28.

Angel K, Provan SA, Hammer HB et al (2011) Changes in arterial stiffness during continued infliximab treatment in patients with inflammatory arthropathies. Fundam Clin Pharmacol 25:511–517. https://doi.org/10.1111/j.1472-8206.2010.00872.xCrossRefPubMed

29.

Cheng IT, Shang Q, Li EK et al (2019) Effect of achieving minimal disease activity on the progression of subclinical atherosclerosis and arterial stiffness: a prospective cohort study in psoriatic arthritis. Arthritis Rheumatol 71:271–280. https://doi.org/10.1002/art.40695CrossRefPubMed

30.

Cheng IT, Li EK, Wong PC et al (2020) Treat to target and prevention of subclinical atherosclerosis in psoriatic arthritis—which target should we choose? Rheumatology (Oxford) 59:2881–2892. https://doi.org/10.1093/rheumatology/keaa025CrossRefPubMed

31.

Brezinski EA, Follansbee MR, Armstrong EJ et al (2014) Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review. Curr Pharm Des 20:513–528. https://doi.org/10.2174/138161282004140213123852CrossRefPubMed

32.

Soy M, Yildiz M, Sevki Uyanik M et al (2009) Susceptibility to atherosclerosis in patients with psoriasis and psoriatic arthritis as determined by carotid–femoral (aortic) pulse-wave velocity measurement. Rev Esp Cardiol 62:96–99. https://doi.org/10.1016/s1885-5857(09)71520-8CrossRefPubMed

33.

Triantafyllias K, Liverakos S, Klonowski A et al (2022) High cardiovascular risk in patients with psoriatic arthritis: evaluation of macroangiopathy and its predictors by aortic pulse wave velocity. Ann Rheum Dis 81:869–870. https://doi.org/10.1136/annrheumdis-2022-eular.2670CrossRef

34.

Costa L, Caso F, D’Elia L et al (2012) Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol 31:711–715. https://doi.org/10.1007/s10067-011-1892-1CrossRefPubMed

35.

Shen J, Shang Q, Li EK et al (2015) Cumulative inflammatory burden is independently associated with increased arterial stiffness in patients with psoriatic arthritis: a prospective study. Arthritis Res Ther 17:75. https://doi.org/10.1186/s13075-015-0570-0CrossRefPubMedPubMedCentral

36.

Imura T, Yamamoto K, Kanamori K et al (1986) Non-invasive ultrasonic measurement of the elastic properties of the human abdominal aorta. Cardiovasc Res 20:208–214. https://doi.org/10.1093/cvr/20.3.208CrossRefPubMed

37.

Yildiz M (2010) Arterial distensibility in chronic inflammatory rheumatic disorders. Open Cardiovasc Med J 4:83–88. https://doi.org/10.2174/1874192401004020083CrossRefPubMedPubMedCentral

38.

Angel K, Provan SA, Gulseth HL et al (2010) Tumor necrosis factor-α antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension 55:333–338. https://doi.org/10.1161/HYPERTENSIONAHA.109.143982CrossRefPubMed

39.

Ludwig M, Petzinger-Kruthoff AV, Buquoy MV et al (2003) Intima-media-dicke der karotisarterien: früher indikator für arteriosklerose und therapeutischer endpunkt. Ultraschall Med 24:162–174. https://doi.org/10.1055/s-2003-40058CrossRefPubMed

40.

Nezu T, Hosomi N, Aoki S et al (2016) Carotid intima-media thickness for atherosclerosis. J Atheroscler Thromb 23:18–31. https://doi.org/10.5551/jat.31989CrossRefPubMed

41.

Kimhi O, Caspi D, Bornstein NM et al (2007) Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 36:203–209. https://doi.org/10.1016/j.semarthrit.2006.09.001CrossRefPubMed

42.

Tam LS, Shang Q, Li EK et al (2008) Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Care Res (Hoboken) 59:1322–1331. https://doi.org/10.1002/art.24014CrossRef

43.

Garg N, Krishan P, Syngle A (2016) Atherosclerosis in psoriatic arthritis: a multiparametric analysis using imaging technique and laboratory markers of inflammation and vascular function. Int J Angiol 25:222–228. https://doi.org/10.1055/s-0036-1584918CrossRefPubMedPubMedCentral

44.

Eder L, Zisman D, Barzilai M et al (2008) Subclinical atherosclerosis in psoriatic arthritis: a case-control study. J Rheumatol 35:877–882PubMed

45.

Fang N, Jiang M, Fan Y (2016) Association between psoriasis and subclinical atherosclerosis. Medicine (Baltimore) 95:e3576. https://doi.org/10.1097/MD.0000000000003576CrossRefPubMed

46.

Lam SHM, Cheng IT, Li EK et al (2020) DAPSA, carotid plaque and cardiovascular events in psoriatic arthritis: a longitudinal study. Ann Rheum Dis 79:1320–1326. https://doi.org/10.1136/annrheumdis-2020-217595CrossRefPubMed

47.

Lucke M, Messner W, Kim ESH et al (2016) The impact of identifying carotid plaque on addressing cardiovascular risk in psoriatic arthritis. Arthritis Res Ther 18:178. https://doi.org/10.1186/s13075-016-1074-2CrossRefPubMedPubMedCentral

48.

Cheng IT, Wong KT, Li EK et al (2020) Comparison of carotid artery ultrasound and Framingham risk score for discriminating coronary artery disease in patients with psoriatic arthritis. RMD Open 6:e001364. https://doi.org/10.1136/rmdopen-2020-001364CrossRefPubMedPubMedCentral

49.

Cheng IT, Meng H, Li M et al (2022) Serum calprotectin level is independently associated with carotid plaque presence in patients with psoriatic arthritis. Front Med (Lausanne) 9:932696. https://doi.org/10.3389/fmed.2022.932696CrossRefPubMed

50.

Eder L, Jayakar J, Shanmugarajah S et al (2013) The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone. Ann Rheum Dis 72:715–720. https://doi.org/10.1136/annrheumdis-2012-201497CrossRefPubMed

51.

Szentpetery A, Healy GM, Brady D et al (2018) Higher coronary plaque burden in psoriatic arthritis is independent of metabolic syndrome and associated with underlying disease severity. Arthritis Rheumatol 70:396–407. https://doi.org/10.1002/art.40389CrossRefPubMed

52.

Miller JM, Rochitte CE, Dewey M et al (2008) Diagnostic performance of coronary angiography by 64-row CT. N Eng J Med 359:2324–2336. https://doi.org/10.1056/NEJMoa0806576CrossRef

53.

Tinggaard AB, Hjuler KF, Andersen IT et al (2021) Prevalence and severity of coronary artery disease linked to prognosis in psoriasis and psoriatic arthritis patients: a multi-centre cohort study. J Intern Med 290:693–703. https://doi.org/10.1111/joim.13311CrossRefPubMed

54.

Shen J, Wong KT, Cheng IT et al (2017) Increased prevalence of coronary plaque in patients with psoriatic arthritis without prior diagnosis of coronary artery disease. Ann Rheum Dis 76:1237–1244. https://doi.org/10.1136/annrheumdis-2016-210390CrossRefPubMed

55.

Haroon M, Szentpetery A, Dodd JD et al (2018) Modifications of cardiovascular risk scores, but not standard risk scores, improve identification of asymptomatic coronary artery disease in psoriatic arthritis. J Rheumatol 45:1329–1330. https://doi.org/10.3899/jrheum.180299CrossRefPubMed

56.

Erre GL, Buscetta G, Paliogiannis P et al (2018) Coronary flow reserve in systemic rheumatic diseases: a systematic review and meta-analysis. Rheumatol Int 38:1179–1190. https://doi.org/10.1007/s00296-018-4039-8CrossRefPubMed

57.

Turiel M, Atzeni F, Tomasoni L et al (2009) Non-invasive assessment of coronary flow reserve and ADMA levels: a case-control study of early rheumatoid arthritis patients. Rheumatology (Oxford) 48:834–839. https://doi.org/10.1093/rheumatology/kep082CrossRefPubMed

58.

Ciftci O, Yilmaz S, Topcu S et al (2008) Impaired coronary microvascular function and increased intima-media thickness in rheumatoid arthritis. Atherosclerosis 198:332–337. https://doi.org/10.1016/j.atherosclerosis.2007.11.013CrossRefPubMed

59.

Kakuta K, Dohi K, Sato Y et al (2016) Chronic inflammatory disease is an independent risk factor for coronary flow velocity reserve impairment unrelated to the processes of coronary artery calcium deposition. J Am Soc Echocardiogr 29:173–180. https://doi.org/10.1016/j.echo.2015.09.001CrossRefPubMed

60.

Liao KP, Huang J, He Z et al (2021) Coronary microvascular dysfunction in rheumatoid arthritis compared to diabetes mellitus and association with all-cause mortality. Arthritis Care Res (Hoboken) 73:159–165. https://doi.org/10.1002/acr.24108.CoronaryCrossRefPubMed

61.

Recio-Mayoral A, Mason JC, Kaski JC et al (2009) Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. Eur Heart J 30:1837–1843. https://doi.org/10.1093/eurheartj/ehp205CrossRefPubMed

62.

Anyfanti P, Gkaliagkousi E, Triantafyllou A et al (2018) Dermal capillary rarefaction as a marker of microvascular damage in patients with rheumatoid arthritis: association with inflammation and disorders of the macrocirculation. Microcirculation 25:e12451. https://doi.org/10.1111/micc.12451CrossRefPubMed

63.

Xu SZ, Wang P, Guan SY et al (2017) Decreased flow-mediated dilatation in patients with rheumatoid arthritis: a meta-analysis. Postgrad Med J 93:260–265. https://doi.org/10.1136/postgradmedj-2016-134068CrossRefPubMed

64.

Chatterjee Adhikari M, Guin A, Chakraborty S et al (2012) Subclinical atherosclerosis and endothelial dysfunction in patients with early rheumatoid arthritis as evidenced by measurement of carotid intima-media thickness and flow-mediated vasodilatation: an observational study. Semin Arthritis Rheum 41:669–675. https://doi.org/10.1016/j.semarthrit.2011.08.003CrossRefPubMed

65.

Gonzalez-Juanatey C, Testa A, Garcia-Castelo A et al (2003) HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 114:647–652. https://doi.org/10.1016/S0002-9343(03)00133-5CrossRefPubMed

66.

Arosio E, De MS, Rigoni A et al (2007) Forearm haemodynamics, arterial stiffness and microcirculatory reactivity in rheumatoid arthritis. J Hypertens 25:1273–1278. https://doi.org/10.1097/HJH.0b013e3280b0157eCrossRefPubMed

67.

Vaudo G, Marchesi S, Gerli R et al (2004) Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 63:31–35. https://doi.org/10.1136/ard.2003.007740CrossRefPubMedPubMedCentral

68.

Lederman MM, Penn-Nicholson A, Cho M et al (2009) Biology of CCR5 and its role in HIV infection and treatment. JAMA 296:815–826. https://doi.org/10.1001/jama.296.7.815CrossRef

69.

Oppermann M (2004) Chemokine receptor CCR5: insights into structure, function, and regulation. Cell Signal 16:1201–1210. https://doi.org/10.1016/j.cellsig.2004.04.007CrossRefPubMed

70.

Schecter AD, Calderon TM, Berman AB et al (2000) Human vascular smooth muscle cells possess functional CCR5. J Biol Chem 275:5466–5471. https://doi.org/10.1074/jbc.275.8.5466CrossRefPubMed

71.

Rodríguez-Rodríguez L, González-Juanatey C, García-Bermúdez M et al (2011) CCR5Δ32 variant and cardiovascular disease in patients with rheumatoid arthritis: a cohort study. Arthritis Res Ther 13:R133. https://doi.org/10.1186/ar3444CrossRefPubMedPubMedCentral

72.

Becetti K, Oeser A, Ormseth MJ et al (2015) Urinary albumin excretion is increased in patients with rheumatoid arthritis and associated with arterial stiffness. J Rheumatol 42:593–598. https://doi.org/10.3899/jrheum.141295CrossRefPubMedPubMedCentral

73.

Petra CV, Albu A, Pamfil C et al (2019) The relationship between epicardial adipose tissue and arterial stiffness in patients with rheumatoid arthritis. Med Ultrason 21:427–434. https://doi.org/10.11152/mu-2001CrossRefPubMed

74.

Berg G, Miksztowicz V, Morales C et al (2019) Epicardial adipose tissue in cardiovascular disease. Adv Exp Med Biol 1127:131–143. https://doi.org/10.1007/978-3-030-11488-6_9CrossRefPubMed

75.

Antonopoulos AS, Antoniades C (2017) The role of epicardial adipose tissue in cardiac biology: classic concepts and emerging roles. J Physiol 595:3907–3917. https://doi.org/10.1113/JP273049CrossRefPubMedPubMedCentral

76.

Ansaldo AM, Montecucco F, Sahebkar A et al (2019) Epicardial adipose tissue and cardiovascular diseases. Int J Cardiol 278:254–260. https://doi.org/10.1016/j.ijcard.2018.09.089CrossRefPubMed

77.

Iacobellis G (2022) Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 19:593–606. https://doi.org/10.1038/s41569-022-00679-9CrossRefPubMedPubMedCentral

78.

Mokotedi L, Gunter S, Robinson C et al (2019) Early wave reflection and pulse wave velocity are associated with diastolic dysfunction in rheumatoid arthritis. J Cardiovasc Transl Res 12:580–590. https://doi.org/10.1007/s12265-019-09892-3CrossRefPubMed

79.

Ilter A, Kiris A, Karkucak M et al (2016) Arterial stiffness is associated with left ventricular dysfunction in patients with rheumatoid arthritis. Clin Rheumatol 35:2663–2668. https://doi.org/10.1007/s10067-015-3163-zCrossRefPubMed

80.

Lo Gullo A, Rodríguez-Carrio J, Aragona CO et al (2018) Subclinical impairment of myocardial and endothelial functionality in very early psoriatic and rheumatoid arthritis patients: association with vitamin D and inflammation. Atherosclerosis 271:214–222. https://doi.org/10.1016/j.atherosclerosis.2018.03.004CrossRefPubMed

81.

van Sijl AM, Peters MJ, Knol DK et al (2011) Carotid intima media thickness in rheumatoid arthritis as compared to control subjects: a meta-analysis. Semin Arthritis Rheum 40:389–397. https://doi.org/10.1016/j.semarthrit.2010.06.006CrossRefPubMed

82.

Wang P, Guan S, Xu S et al (2016) Increased carotid intima-media thickness in rheumatoid arthritis: an update meta-analysis. Clin Rheumatol 35:315–323. https://doi.org/10.1007/s10067-015-3130-8CrossRefPubMed

83.

Gonzalez-Gay MA, Gonzalez-Juanatey C, Piñeiro A et al (2005) High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol 32:1219–1223PubMed

84.

Hannawi S, Haluska B, Marwick TH et al (2007) Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation. Arthritis Res Ther 9:1–9. https://doi.org/10.1186/ar2323CrossRef

85.

Pahor A, Hojs R, Gorenjak M et al (2006) Accelerated atherosclerosis in pre-menopausal female patients with rheumatoid arthritis. Rheumatol Int 27:119–123. https://doi.org/10.1007/s00296-006-0176-6CrossRefPubMed

86.

la Montagna G, Cacciapuoti F, Buono R et al (2007) Insulin resistance is an independent risk factor for atherosclerosis in rheumatoid arthritis. Diabetes Vasc Dis Res 4:130–135. https://doi.org/10.3132/dvdr.2007.031CrossRef

87.

Pingiotti E, Cipriani P, Marrelli A et al (2007) Surface expression of fractalkine receptor (CX3CR1) on CD4+/CD28− T cells in RA patients and correlation with atherosclerotic damage. Ann N Y Acad Sci 1107:32–41. https://doi.org/10.1196/annals.1381.004CrossRefPubMed

88.

Dumitriu IE, Baruah P, Finlayson CJ et al (2012) High levels of costimulatory receptors OX40 and 4–1BB characterize CD4+CD28 null T cells in patients with acute coronary syndrome. Circ Res 110:857–869. https://doi.org/10.1161/CIRCRESAHA.111.261933CrossRefPubMed

89.

Liuzzo G, Goronzy JJ, Yang H et al (2000) Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 101:2883–2888. https://doi.org/10.1161/01.cir.101.25.2883CrossRefPubMed

90.

Umehara H, Bloom ET, Okazaki T et al (2004) Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol 24:34–40. https://doi.org/10.1161/01.ATV.0000095360.62479.1FCrossRefPubMed

91.

Jókai H, Szakonyi J, Kontár O et al (2013) Impact of effective tumor necrosis factor-alfa inhibitor treatment on arterial intima-media thickness in psoriasis: results of a pilot study. J Am Acad Dermatol 69:523–529. https://doi.org/10.1016/j.jaad.2013.06.019CrossRefPubMed

92.

Markelova EI, Novikova DS, Korotaeva T et al (2018) Dynamics of carotid intima-media thickness, parameters of arterial stiffness and ambulatory blood pressure monitoring during therapy with inhibitor of tumor necrosis factor-alpha in patients with early psoriatic arthritis. Ration Pharmacother Cardiol 14:711–715. https://doi.org/10.20996/1819-6446-2018-14-5-711-715CrossRef

93.

Solomon DH, Reed GW, Kremer JM et al (2015) Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol 67:1449–1455. https://doi.org/10.1002/art.39098CrossRefPubMedPubMedCentral

94.

del Rincón I, Williams K, Stern MP et al (2003) Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 48:1833–1840. https://doi.org/10.1002/art.11078CrossRefPubMed

95.

Kobayashi H, Giles JT, Polak JF et al (2010) Increased prevalence of carotid artery atherosclerosis in rheumatoid arthritis is artery-specific. J Rheumatol 37:730–739. https://doi.org/10.3899/jrheum.090670CrossRefPubMed

96.

Evans MR, Escalante A, Battafarano DF et al (2011) Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid arthritis. Arthritis Rheum 63:1211–1220. https://doi.org/10.1002/art.30265CrossRefPubMedPubMedCentral

97.

Charles-Schoeman C (2012) Cardiovascular disease and rheumatoid arthritis: an update. Curr Rheumatol Rep 14:455–462. https://doi.org/10.1007/s11926-012-0271-5CrossRefPubMedPubMedCentral

98.

Karpouzas GA, Bui VL, Ronda N et al (2021) Biologics and atherosclerotic cardiovascular risk in rheumatoid arthritis: a review of evidence and mechanistic insights. Expert Rev Clin Immunol 17:355–374. https://doi.org/10.1080/1744666X.2021.1899809CrossRefPubMed

99.

Mal K, Kumar R, Mansoor F et al (2020) Risk of major adverse cardiovascular events in patients with rheumatoid arthritis. Cureus 12:e12246. https://doi.org/10.7759/cureus.12246CrossRefPubMedPubMedCentral

100.

Palmou-Fontana N, Martínez-Lopez D, Corrales A et al (2020) Disease activity influences cardiovascular risk reclassification based on carotid ultrasound in patients with psoriatic arthritis. J Rheumatol 47:1344–1353. https://doi.org/10.3899/jrheum.190729CrossRefPubMed

101.

Eder L, Chandran V, Gladman DD (2013) The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. Ann Rheum Dis 73:1990–1996. https://doi.org/10.1136/annrheumdisCrossRefPubMed

102.

Ibáñez-Bosch R, Restrepo-Velez J, Medina-Malone M et al (2017) High prevalence of subclinical atherosclerosis in psoriatic arthritis patients: a study based on carotid ultrasound. Rheumatol Int 37:107–112. https://doi.org/10.1007/s00296-016-3617-xCrossRefPubMed

103.

Ramonda R, Puato M, Punzi L et al (2014) Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: a two-year prospective observational study. Jt Bone Spine 81:421–425. https://doi.org/10.1016/j.jbspin.2014.02.005CrossRef

Title: Endothelial dysfunction and risk factors for atherosclerosis in psoriatic arthritis: overview and comparison with rheumatoid arthritis
Authors: Konrad Kaleta
Julia Krupa
Wiktoria Suchy
Anna Sopel
Mariusz Korkosz
Jarosław Nowakowski
Publication date: 24-03-2024
Publisher: Springer Berlin Heidelberg
Keywords: Psoriatic Arthritis
Rheumatoid Arthritis
Arterial Occlusive Disease
Vulgar Psoriasis
Arthritis
Published in: Rheumatology International
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-024-05556-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com